Literature DB >> 1902319

Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma.

C S Wong1, J Van Dyk, W J Simpson.   

Abstract

From 1975 to 1982, 32 patients with a diagnosis of anaplastic carcinoma of the thyroid were entered into a protocol of hyperfractionated accelerated radiotherapy. The tumor dose was 30-45 Gy at 1 Gy per fraction given 4 times a day at 3-h intervals. The results were disappointing with a median survival of less than 6 months. Two patients developed radiation myelopathy at 8 and 13 months, total spinal cord dose being 39.9 and 48.3 Gy, respectively. The risk of spinal cord damage was much higher than expected. The possible radiobiological causes and clinical implications are discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1902319     DOI: 10.1016/0167-8140(91)90105-p

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

Review 2.  The use of radiation in the management of spinal metastases.

Authors:  C M Faul; J C Flickinger
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.

Authors:  J J Beitler; S Wadler; H Haynes; S Fell; A Rozenblit; E Wolf; B A Levine
Journal:  Med Oncol       Date:  1995-06       Impact factor: 3.064

4.  A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients.

Authors:  B Busnardo; O Daniele; M R Pelizzo; R Mazzarotto; D Nacamulli; D Devido; C Mian; M E Girelli
Journal:  J Endocrinol Invest       Date:  2000-12       Impact factor: 4.256

Review 5.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

Review 6.  Surgical options in undifferentiated thyroid carcinoma.

Authors:  Brian Hung-Hin Lang; Chung-Yau Lo
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

7.  Approach to the patient with anaplastic thyroid carcinoma.

Authors:  Robert C Smallridge
Journal:  J Clin Endocrinol Metab       Date:  2012-08       Impact factor: 5.958

8.  Anaplastic thyroid carcinoma.

Authors:  Augusto Taccaliti; Francesca Silvetti; Gioia Palmonella; Marco Boscaro
Journal:  Front Endocrinol (Lausanne)       Date:  2012-07-05       Impact factor: 5.555

Review 9.  New trends in the treatment of undifferentiated carcinomas of the thyroid.

Authors:  Paolo Miccoli; Gabriele Materazzi; Alessandro Antonelli; Erica Panicucci; Gianluca Frustaci; Piero Berti
Journal:  Langenbecks Arch Surg       Date:  2006-11-28       Impact factor: 2.895

10.  Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment.

Authors:  Govardhanan Nagaiah; Akm Hossain; Colin J Mooney; James Parmentier; Scot C Remick
Journal:  J Oncol       Date:  2011-06-12       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.